Dr. Misbah U. Qadir
Claim this profileVidant Oncology-Kinston
Studies Lung Cancer
Studies Cancer
37 reported clinical trials
71 drugs studied
About Misbah U. Qadir
Education:
- Graduated from King Edward Medical University, Pakistan.
- Completed Residency in Internal Medicine at East Carolina University Brody School of Medicine, Greenville, NC.
- Undertook a Fellowship in Hematology/Oncology at East Carolina University Brody School of Medicine, Greenville, NC.
Experience:
- Currently affiliated with Vidant Oncology - Kinston.
Area of expertise
1Lung Cancer
Stage IV
Stage III
Stage I
2Cancer
Stage IV
PD-L1 positive
Stage III
Affiliated Hospitals
Clinical Trials Misbah U. Qadir is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
More about Misbah U. Qadir
Clinical Trial Related6 years of experience running clinical trials · Led 37 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Misbah U. Qadir has experience with
- Nivolumab
- Atezolizumab
- Fluorouracil
- Ipilimumab
- Carboplatin
- Cisplatin
Breakdown of trials Misbah U. Qadir has run
Lung Cancer
Cancer
Pancreatic Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Misbah U. Qadir specialize in?
Misbah U. Qadir focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Misbah U. Qadir currently recruiting for clinical trials?
Yes, Misbah U. Qadir is currently recruiting for 10 clinical trials in Kinston North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Misbah U. Qadir has studied deeply?
Yes, Misbah U. Qadir has studied treatments such as Nivolumab, Atezolizumab, Fluorouracil.
What is the best way to schedule an appointment with Misbah U. Qadir?
Apply for one of the trials that Misbah U. Qadir is conducting.
What is the office address of Misbah U. Qadir?
The office of Misbah U. Qadir is located at: Vidant Oncology-Kinston, Kinston, North Carolina 28501 United States. This is the address for their practice at the Vidant Oncology-Kinston.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.